Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FD-IMPACT: Novel Immunotherapies for Pancreatic Cancer
NCT06370754Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab, JS007, JS015 in pancreatic cancer (PC), sponsored by Fudan University. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tifcemalimabJS007JS015
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06370754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370754.